Tracer shows promise for imaging of prostate tumors

11/7/2013 |

F-18 aluminum-fluoride radiolabeled bombesin analog NODAGA-RM1 showed strong cancer-imaging properties and serum stability compared with Cu-64 NODAGA-RM1, making it a potentially effective tool for PET imaging of prostate cancer. The F-18 AlF-NODAGA-RM1 tracer binds to gastrin-releasing peptide receptors and had a higher tumor uptake value of 4.6 at 30 minutes, 4.0 at one hour and 3.9 at two hours, according to results of a comparative study published in the Journal of Nuclear Medicine.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA